Please login to the form below

Not currently logged in

Cannabis medicines for Alzheimer's disease

Patients suffering from Alzheimer's disease could be treated with cannabis according to new research data

Patients suffering from Alzheimer's disease could be treated with cannabis according to new research data.

During a symposium at the Royal Pharmaceutical Society of Great Britain (RPSGB) on March 10, Professor Raphael Mechoulam of the Hebrew University of Jerusalem presented findings that indicated the potential benefits of cannabis-derived medicines.

Research, which is still in early stages, shows that the chemicals present in cannabis can slow down memory loss, the most prevalent feature of Alzheimer's disease.

Professor Tony Moffat, chairperson of the RPSGB symposium, said: "Although recent press coverage has focused on the abuses associated with the plant, cannabis-derived medications may offer novel opportunities in drug discovery.

"There is currently considerable interest in the medical benefits of cannabis and related compounds for a range of conditions including arthritis, multiple sclerosis and neurological pain."

Alzheimer's disease is the most common form of dementia and affects 417,000 people in the UK and 24.3mn across the world.

The trails conducted so far have only shown the effect of cannabis medicines on mice, but the next step for researchers will be to initiate human patient studies.

10th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...